Moreover, by measuring standardised uptake values (SUV) of [68Ga]Ga-PSMA-617 in the tumour and in the healthy contralateral brain tissue, TLR and tumour-to-salivary glands (TSG) ratio, this study aims to explore the potential of PSMA-617 as a candidate ligand for targeted radionuclide therapy with α/β-emitters in patients with recurrent GBM. Here, FOLH1 is linked to neoplasm.